scholarly journals Cancer-associated thrombosis: the when, how and why

2019 ◽  
Vol 28 (151) ◽  
pp. 180119 ◽  
Author(s):  
Caio J. Fernandes ◽  
Luciana T. K. Morinaga ◽  
José L. Alves ◽  
Marcela A. Castro ◽  
Daniela Calderaro ◽  
...  

Cancer-associated thrombosis (CAT) is a condition in which relevance has been increasingly recognised both for physicians that deal with venous thromboembolism (VTE) and for oncologists. It is currently estimated that the annual incidence of VTE in patients with cancer is 0.5% compared to 0.1% in the general population. Active cancer accounts for 20% of the overall incidence of VTE. Of note, VTE is the second most prevalent cause of death in cancer, second only to the progression of the disease, and cancer is the most prevalent cause of deaths in VTE patients. Nevertheless, CAT presents several peculiarities that distinguish it from other VTE, both in pathophysiology mechanisms, risk factors and especially in treatment, which need to be considered. CAT data will be reviewed in this review.

2020 ◽  
Vol 120 (05) ◽  
pp. 847-856 ◽  
Author(s):  
Michela Giustozzi ◽  
Antonio Curcio ◽  
Bob Weijs ◽  
Thalia S. Field ◽  
Saulius Sudikas ◽  
...  

Abstract Background Venous thromboembolism (VTE) is a major cause of death in cancer patients. Although patients with cancer have numerous risk factors for VTE, the relative contribution of cancer treatments is unclear. Objective The objective of this study is to evaluate the association between cancer therapies and the risk of VTE. Methods From UK Clinical Practice Research Datalink, data on patients with first cancer diagnosis between 2008 and 2016 were extracted along with information on hospitalization, treatments, and cause of death. Primary outcome was active cancer-associated VTE. To establish the independent effects of risk factors, adjusted subhazard ratios (adj-SHR) were calculated using Fine and Gray regression analysis accounting for death as competing risk. Results Among 67,801 patients with a first cancer diagnosis, active cancer-associated VTE occurred in 1,473 (2.2%). During a median observation time of 1.2 years, chemotherapy, surgery, hormonal therapy, radiation therapy, and immunotherapy were given to 71.1, 37.2, 17.2, 17.5, and 1.4% of patients with VTE, respectively. The active cancers associated with the highest risk of VTE—as assessed by incidence rates—included pancreatic cancer, brain cancer, and metastatic cancer. Chemotherapy was associated with an increased risk of VTE (adj-SHR: 3.17, 95% confidence interval [CI]: 2.76–3.65) while immunotherapy with a not significant reduced risk (adj-SHR: 0.67, 95% CI: 0.30–1.52). There was no association between VTE and radiation therapy (adj-SHR: 0.91, 95% CI: 0.65–1.27) and hormonal therapies. Conclusion VTE risk varies with cancer type. Chemotherapy was associated with an increased VTE risk, whereas with radiation and immunotherapy therapy, an association was not confirmed.


2016 ◽  
Vol 139 ◽  
pp. 29-37 ◽  
Author(s):  
Aneel A. Ashrani ◽  
Rachel E. Gullerud ◽  
Tanya M. Petterson ◽  
Randolph S. Marks ◽  
Kent R. Bailey ◽  
...  

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 13-13
Author(s):  
Caroline Padbury ◽  
Margaret Harris ◽  
Michael LaCouture ◽  
Jelena Spyropoulos

Title:Success of Online CME at Improving Knowledge and Confidence Around Guideline-Directed Management of Cancer-Associated Thrombosis Study Objectives:Recent guidance statements recommend the use of direct oral anticoagulants (DOACs) as primary thromboprophylaxis in ambulatory patients with cancer who are starting chemotherapy and in patients with cancer and acute venous thromboembolism at low risk of bleeding and no drug-drug interactions.[Farge 2019; Key 2020] Yet, many clinicians lack knowledge and confidence with integrating DOACs into management strategies for patients with cancer in accordance to guideline recommendations.[Cushman 2015; Khorana 2016] We sought to determine if online continuing medical education (CME) could improve the knowledge and confidence of hematologists/oncologists regarding guideline-directed use of DOACs in the management of cancer-associated thrombosis. Methods:This CME intervention comprised of a 30-minute online video-based roundtable discussion among experts in the field of cancer-associated thrombosis management. Responses to 3 multiple-choice, knowledge questions and 1 self-efficacy, 5-point Likert scale confidence question were analyzed using a repeated pairs pre-/post-assessment study design. A chi-square test (P <.05 is considered significant) assessed pre- to post-activity change . The activity launched December 23, 2019, and data were collected through February 24, 2020. Results:In total, 71 Hematologists/Oncologists were included in this study. Overall, there were knowledge and confidence improvements seen among all groups from pre- to post-assessment: 27% of hematologists/oncologists (P<.01) improved at identifying guideline-directed therapy regarding recommended thromboprophylaxis in patients with cancer per guideline recommendations.27% of hematologists/oncologists (P<.01) improved at selecting guideline-appropriate treatment options for cancer-associated thrombosis.44% of hematologists/oncologists had an increase in confidence in managing thrombosis in patients with cancer. Continued educational gaps: 25% of hematologists/oncologists failed to select guideline recommended DOAC therapy for thromboprophylaxis in cancer patients.45% of hematologists/oncologists failed to select guideline recommended DOAC therapy for treatment of thrombosis in cancer patients.66% of hematologists/oncologists still remain at only a rating of 1 to 3 on a scale of 1 to 5 in their confidence managing thrombosis in patients with cancer. Conclusion:This study demonstrates the success of online, CME-accredited, video-based roundtable discussion with experts in the field on significantly improving knowledge and confidence of hematologists/oncologists related to the guideline-recommended use of DOACs in the management of cancer-associated thrombosis. Continued gaps were also identified for future educational targets. Sources of support: Developed through an independent educational grant from Janssen in partnership with the University of Chicago. References: Cushman M, Creager MA. Improving awareness and outcomes related to venous thromboembolism. JAMA. 2015;314(18):1913-4. Farge D, Frere C, Connors JM, et al. 2019 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. The Lancet Oncology. 2019;20(10):e566-581. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 Feb 10;38(5):496-520. Khorana AA, Yannicelli D, McCrae KR, et al. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016 Sep;145:51-3. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 123 (25) ◽  
pp. 3972-3978 ◽  
Author(s):  
Cheng E. Chee ◽  
Aneel A. Ashrani ◽  
Randolph S. Marks ◽  
Tanya M. Petterson ◽  
Kent R. Bailey ◽  
...  

Key Points VTE recurrence risk in patients with cancer can be stratified by cancer type, stage, stage progression, and presence of leg paresis. Patients with cancer at high VTE recurrence risk should be considered for secondary prophylaxis.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 1097-1097
Author(s):  
David Spirk ◽  
Wolfgang Korte ◽  
Marc Husmann ◽  
Beat Frauchiger ◽  
Martin Banyai ◽  
...  

Abstract Abstract 1097 Background: In patients with cancer and acute venous thromboembolism (VTE), current consensus guidelines recommend anticoagulation therapy for an indefinite duration or until the cancer is resolved. Methods and results: Among 1’247 patients with acute VTE enrolled in the Swiss Venous Thromboembolism Registry (SWIVTER) from 18 hospitals, 315 (25%) had cancer of whom 179 (57%) had metastatic disease, 159 (50%) ongoing or recent chemotherapy, and 83 (26%) tumor surgery within 6 months. Patients with cancer were older (66±14 vs. 60±19 years, p<0.001), more often hospitalized at the time of VTE diagnosis (46% vs. 36%, p=0.001), immobile for >3 days (25% vs. 16%, p<0.001), and more often had thrombocytopenia (6% vs. 1%, p<0.001) than patients without cancer. The 30-day rate of VTE-related death or recurrent VTE was 9% in cancer patients vs. 4% in patients without cancer (p<0.001), and the rates of bleeding requiring medical attention were 5% in both groups (p=0.57). Cancer patients received indefinite-duration anticoagulation treatment more often than patients without cancer (47% vs. 19%, p<0.001), and LMWH mono-therapy during the initial 3 months was prescribed to 45% vs. 8%, p<0.001, respectively. Among patients with cancer, prior VTE (OR 4.0, 95%CI 2.0–8.0), metastatic disease (OR 3.0, 95%CI 1.7–5.2), outpatient status at the time of VTE diagnosis (OR 3.8, 95%CI 1.9–7.6), and inpatient treatment (OR 4.4, 95%CI 2.1–9.2) were independently associated with the prescription of indefinite-duration anticoagulation treatment. Conclusions: Less than half of the cancer patients with acute VTE received a prescription for indefinite-duration anticoagulation treatment. Recurrent VTE, metastatic cancer, outpatient VTE diagnosis, and VTE requiring hospitalization were associated with an increased use of this strategy. Disclosures: Spirk: sanofi-aventis (suisse) sa: Employment.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4256-4256
Author(s):  
Thomas L. Ortel ◽  
Michele Beckman ◽  
Lawrence Muhlbaier ◽  
Nimia Reyes ◽  
Althea Grant ◽  
...  

Abstract Introduction: Venous thromboembolism (VTE), defined as deep vein thrombosis (DVT), pulmonary embolism (PE), or both, has been estimated to affect 300,000 to 600,000 individuals in the US each year. Incidence estimates suggest that African Americans have similar, or slightly higher, rates of VTE compared to Whites, while Asians appear to have a lower rate (Beckman, et al., Am J Prev Med, 2010;38:S495-S501). Acquired risk factors for VTE can be identified in ~50% of cases. Using a population-based approach, we used multiple case finding techniques to improve estimates of VTE occurrence in a geographically defined, racially diverse population. Methods: Durham County, NC, has a population of ~280,000 individuals, characterized as: 52.4% female; 53% White, 38.8% African American, 4.9% Asian, 1% American Indian, and 2.2% ≥2 races; and 13.5% Hispanic (US Census Data, 2012). The County is served by three hospitals, two in the Duke University Health System (DUHS) that share an electronic medical record, and the Durham Veterans’ Administration Medical Center (VAMC). We used a combination of methods to systematically identify patients living in Durham County with a new diagnosis of VTE. These included direct review of imaging data in the Duke Picture Archive and Communication System (PACS); automated review of ICD9 diagnosis codes for VTE and CPT codes for imaging procedures used for diagnosing DVT and PE stored in the Duke Medicine Enterprise Data Warehouse via the Duke Enterprise Data Unified Content Explorer (DEDUCE); direct review of Duke autopsy reports; and review of Veterans Health Information Systems and Technology Architecture (VISTA) to identify cases at the VAMC. Individual patients and events were cross-referenced to avoid duplicate entries, and demographic, risk factor, and treatment data were collected by record review and entered into a REDCap database. Data for the 9 month period from March through November 2013 collected at the DUHS hospitals are included in this abstract. Results: During the study period, we identified a total of 273 unique individuals with VTE, resulting in an estimated annual incidence of 1.3 per 1,000 individuals in Durham County. The mean age of the patients was 61.6 years (range, 19 to 99 years), and 153 (56%) were female. Mean BMI was 29.5±8.4. Racial distribution of VTE and estimated annual incidence is shown in the table below. Table 1RacePatients, n (%)Estimated annual incidence per 1,000 populationAsian2 (0.73%)0.19African American164 (60%)2.01White104 (38%)0.93Other3 (1.1%)0.45 Characteristics of some of the events and risk factors comparing African American and White patients are shown in the table below. Abstract 4256. Table 2Total (total n=273)African American (total n=164)White (total n=104)Pulmonary emboli141/271 (52%)91/163 (55.8%)48/103 (46.6%)History of prior VTE63/273 (23%)38/162 (23.2%)25/103 (24%)Surgery within the preceding 90 days103/238 (43%)55/151 (36.4%)34/92 (38.0%)Active cancer57/246 (23%)38/153 (24.8%)18/89 (20.2%)Catheter-related17/250 (7%)11/148 (7.4%)6/88 (6.8%) None of these comparisons were statistically significant. Three African American patients had sickle cell disease. Hypertension (p=0.0392) and end-stage renal disease (p=0.0038) occurred more frequently in African American VTE patients compared to White VTE patients. Most patients were treated with anticoagulant therapy at the time of diagnosis (n=236; 87%), including low-molecular weight heparin (n=167; 70.8%), unfractionated heparin (n=78; 33.1%), and rivaroxaban (n=21; 8.9%); some patients received more than 1 agent. 129 patients (54.7%) were started on warfarin at the time of diagnosis. A minority of patients were treated with thrombolytic therapy (n=7; 2.6%), thrombectomy/embolectomy (n=3; 1.1%), or placement of an IVC filter (n=19; 7%). Major bleeding occurred in 6 patients (2.2%). These estimates are subject to limitations. They do not include Durham County residents who were diagnosed and treated completely outside the county, and cases from the Durham VAMC are pending. Conclusions: Our VTE surveillance case finding approach resulted in an estimated annual VTE incidence of ~1.3 persons per 1,000 per year, with an incidence in African Americans that is approximately twice the incidence in Whites. Common risk factors were similar for African Americans and Whites, but hypertension and end-stage renal disease were more common comorbid conditions in African Americans. Disclosures No relevant conflicts of interest to declare.


Author(s):  
Gary H. Lyman ◽  
Alok A. Khorana ◽  
Anna Falanga

The American Society of Clinical Oncology (ASCO) recently updated clinical practice guidelines on the treatment and prevention of venous thromboembolism (VTE) in patients with cancer. Although several new studies have been reported, many questions remain about the close relationship between VTE and malignant disease. The risk of VTE among patients with cancer continues to increase and is clearly linked to patient-, disease- and treatment-specific factors. In general, VTE among patients with cancer is treated in a similar fashion to that in other patient populations. However, the greater risk of VTE in patients with cancer, the multitude of risk factors, and the greater risk of VTE recurrence and mortality among patients with cancer pose important challenges for surgeons, oncologists, and other providers.


2015 ◽  
Vol 114 (07) ◽  
pp. 150-157 ◽  
Author(s):  
Samuel Z. Goldhaber ◽  
Clive Kearon ◽  
Ajay K. Kakkar ◽  
Sebastian Schellong ◽  
Henry Eriksson ◽  
...  

SummaryThe efficacy and safety of dabigatran for treatment of venous thromboembolism (VTE) were demonstrated in two trials. It is unclear if the results pertain to patients with cancer and VTE. Data from two randomised trials comparing dabigatran and warfarin for acute VTE were pooled. Primary efficacy outcome was symptomatic recurrent VTE and related death from randomisation to the end of the treatment period. Safety outcomes were major, major and clinically relevant non-major, and any bleeding during the oral-only treatment period. Patients with active cancer (=within 5 years) at baseline or diagnosed during the study were analysed. Compared with 4,772 patients without cancer, recurrent VTE occurred more frequently in 335 patients with cancer at any time (hazard ratio [HR] 3.3; 95 % confidence interval [CI], 2.1–5.3) and more often in 114 with cancer diagnosed during the study compared to 221 with cancer at baseline (HR 2.6; 95 % CI, 1.1–6.2). There was no significant difference in efficacy between dabigatran and warfarin for cancer at baseline (HR 0.75; 95 % CI, 0.20–2.8) or diagnosed during the study (HR 0.63; 95 % CI, 0.20–2.0). Major bleeding (HR 4.1; 95 % CI, 2.2–7.5) and any bleeding (HR 1.5; 95 % CI, 1.2–2.0) were more frequent in patients with cancer than without, but with similar incidence in cancer with dabigatran or warfarin. In conclusion, in cancer patients, dabigatran provided similar clinical benefit as warfarin. VTE recurrence or bleeding were similar in patients on dabigatran or warfarin. The efficacy of dabigatran has not been assessed in comparison with low-molecular-weight heparin.


2021 ◽  
Vol 17 (3) ◽  
pp. 376-385
Author(s):  
K. V. Lobastov ◽  
A. R. Navasardyan ◽  
I. V. Schastlivtsev

Aim. To assess the duration of the anticoagulant treatment of venous thromboembolism (VTE) in various categories of patients in real clinical practice through survey of practitioners, as well as correspondence of the duration with current clinical guidelines.Material and methods. Data obtained from electronic survey of practicing surgeons as part of a commercial brand assessment (Brand Adoption Monitor) was studied. Survey was carried out by the "Validata” analytical agency at the request and with the financial support of Bayer. Inpatient and outpatient vascular surgeons, as well as general outpatient surgeons were invited to complete the electronic questionnaire. The number of interviewed specialists was 100: 50 inpatient vascular surgeons and 50 outpatient specialists, among whom the share of vascular surgeons (phlebologists, angi-ologists) was about 20%. The study was completed in 20 cities of Russia with a population of at least 200,000 people from all federal districts except the North Caucasus and the Republic of Crimea. The selection criteria for participants were: work experience in the specialty ≥3 years, work experience at the current organization >6 months, ≥5 patients with VTE during in the last month.Results. In total, 104 doctors were surveyed during the period from December 11, 2019 to January 20, 2020, of which 50 were inpatient vascular surgeons and 54 were from outpatient setting. According to the survey of vascular surgeons in hospitals, 75% (6 [5;10]) of patients were hospitalized with a primary episode of VTE and 25% (2 [1;4]) with a recurrent thrombotic event. In an outpatient surgeon, 27.5% (3 [2;5]) of patients were treated in an outpatient setting without hospitalization, 34.7% (3 [2;5]) came to an appointment immediately after discharge from the hospital and 38.8% (2 [1;4]) were a repeat visit regarding a previous VTE. Most often, surgeons observed episodes of clinically unprovoked VTE in 27.3% of cases, thrombotic events provoked by major transient risk factors were 12.2%, event provoked by small transient risk factors were 13.3% and events provoked by small persistent risk factors were 12.6%, while cancer-associated thrombosis represented 13.5%. Most surgeons chose to prescribe anticoagulant therapy beyond 3 months. About half of the specialists prescribed therapy for a year or longer for cancer-associated thrombosis and recurrent VTE. When treating the first episode of clinically unprovoked VTE, about half of the respondents chose anticoagulation for a period of 3 to 6 months. About 60% of specialists prescribed anticoagulant therapy for a period of 3 to 6 months to patients with minor transient or persistent risk factors and patients with VTE provoked by major transient risk factor (trauma or surgery).Conclusion. Correspondence of the duration of anticoagulant therapy in real clinical practice with the international clinical guidelines varies within 450% range and, on average, does not exceed 30%. This discrepancy was both in situations when the duration of therapy was lower than recommended, but also in situations when treatment extension would not have been recommended.


Sign in / Sign up

Export Citation Format

Share Document